Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis

類似資料

• Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
  著者:: van der Heijde, D, 等
  出版事項: (2008)
• Palaeopathology of spinal osteophytosis, vertebral ankylosis, ankylosing spondylitis, and vertebral hyperostosis.
  著者:: Rogers, J, 等
  出版事項: (1985)
• Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab
  著者:: van der Heijde, Désirée, 等
  出版事項: (2015)
• Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
  著者:: Braun, J, 等
  出版事項: (2002)
• Treatment trials in ankylosing spondylitis: current and future considerations
  著者:: van der Heijde, D, 等
  出版事項: (2002)